Benefit of Niraparib Maintenance May Extend Beyond First Progression in Ovarian Cancer
There was an improvement in second progression-free survival, but not overall survival, with niraparib.
Ovarian Cancer
Atezolizumab Does Not Prolong Progression-Free Survival in Newly Diagnosed, Advanced Ovarian Cancer
There was no benefit with atezolizumab, regardless of PD-L1 status.
Carboplatin Monotherapy Proves Inferior to Standard Therapy in Vulnerable Older Patients With Ovarian Cancer
Progression-free and overall survival were inferior with single-agent carboplatin.
Universal Genetic Testing Is Far From a Reality in Patients With Ovarian Cancer
A new review points to low rates of genetic testing in patients with ovarian cancer.
Injection May Illuminate Hard-to-Spot Ovarian Cancer Lesions for Surgical Resection
One-third of patients had an additional lesion removed with use of pafolacianine sodium.
Mirvetuximab Soravtansine Plus Bevacizumab Looks Promising in Platinum-Agnostic Ovarian Cancer
The combination produced durable responses in patients with high folate receptor alpha expression.
Secondary Cytoreduction Improves Progression-Free Survival in Platinum-Sensitive, Relapsed Ovarian Cancer
The median progression-free survival was nearly 6 months longer in patients who underwent surgery.
Lack of Standardized Screening Linked to Increased Incidence of Many HPV-Related Cancers
For HPV-related cancers without standardized screening, incidence rates increased between 2001 and 2017.
Maintenance Therapy With Olaparib Improves Survival in Relapsed Ovarian Cancer
Investigators performed a final analysis of SOLO2 to investigate the effect of olaparib on overall survival in patients with ovarian cancer and a BRCA1/2 mutation.
PARP Inhibitor Maintenance Improves PFS in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer
Maintenance with a PARP inhibitor benefited all subsets of patients
- Loading...
Loading...
Next post in Gynecologic Cancer
Loading... 
Loading...